A detailed history of Sg Americas Securities, LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Sg Americas Securities, LLC holds 89,325 shares of RXRX stock, worth $571,680. This represents 0.0% of its overall portfolio holdings.

Number of Shares
89,325
Previous 25,598 248.95%
Holding current value
$571,680
Previous $192,000 206.77%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 03, 2024

BUY
$5.92 - $8.6 $377,263 - $548,052
63,727 Added 248.95%
89,325 $589,000
Q2 2024

Jul 12, 2024

BUY
$7.35 - $10.05 $188,145 - $257,259
25,598 New
25,598 $192,000
Q4 2023

Jan 12, 2024

SELL
$5.09 - $10.79 $85,211 - $180,635
-16,741 Reduced 43.01%
22,186 $219,000
Q3 2023

Oct 13, 2023

BUY
$6.59 - $15.86 $44,930 - $108,133
6,818 Added 21.23%
38,927 $298,000
Q2 2023

Jul 10, 2023

SELL
$4.56 - $9.94 $104,428 - $227,635
-22,901 Reduced 41.63%
32,109 $240,000
Q1 2023

Apr 28, 2023

BUY
$6.42 - $9.64 $173,262 - $260,164
26,988 Added 96.31%
55,010 $367,000
Q4 2022

Feb 02, 2023

BUY
$7.16 - $12.7 $70,755 - $125,501
9,882 Added 54.48%
28,022 $216,000
Q3 2022

Oct 31, 2022

BUY
$7.83 - $13.6 $49,900 - $86,672
6,373 Added 54.16%
18,140 $193,000
Q2 2022

Jul 29, 2022

BUY
$5.04 - $9.26 $59,305 - $108,962
11,767 New
11,767 $96,000
Q1 2022

Apr 29, 2022

SELL
$6.16 - $18.03 $140,706 - $411,841
-22,842 Closed
0 $0
Q4 2021

Feb 07, 2022

BUY
$16.14 - $21.86 $170,696 - $231,191
10,576 Added 86.22%
22,842 $391,000
Q3 2021

Nov 01, 2021

BUY
$19.03 - $41.33 $233,421 - $506,953
12,266 New
12,266 $282,000

Others Institutions Holding RXRX

About RECURSION PHARMACEUTICALS, INC.


  • Ticker RXRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 180,480,000
  • Market Cap $1.16B
  • Description
  • Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...
More about RXRX
Track This Portfolio

Track Sg Americas Securities, LLC Portfolio

Follow Sg Americas Securities, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sg Americas Securities, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sg Americas Securities, LLC with notifications on news.